Innovations in Neurocritical Care
At Mneuro, we aspire to be the total solutions company providing innovation in neuroinformatics and procedural technologies to help improve outcomes and efficiencies across the continuum of care for neuro ICU patients. Our portfolio is built on an expert understanding of desired outcomes and intense focus on unmet needs of Neurocritical Care physicians and their teams.
Cerebrospinal Fluid Treatment Platform
Our mission for the Mneuro Cerebrospinal Fluid (CSF) Treatment Platform is to develop a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.
The Mneuro CSF Treatment Platform
The Mneuro CSF Treatment Platform offers a tailored process for the treatment and return of cerebrospinal fluid, called Neurapheresis™ Therapy.
Using Neurapheresis Therapy in post-subarachnoid hemorrhage (SAH) patients is intended to rapidly remove red blood cells from the CSF shortly after SAH securement. The removal of degrading red blood cells and their released cytotoxic byproducts may be accomplished more efficiently with Neurapheresis Therapy than with standard gravity-dependent drains.
It is theorized that early, rapid filtration of red blood cells post-SAH may reduce the incidence of cerebral vasospasm and thus may contribute to a shorter length of stay, less utilization of hospital resources, improved clinical functional outcomes, and an overall reduced healthcare economic burden.1
The Mneuro CSF Treatment Platform is currently in a feasibility trial.
What is Subarachnoid Hemorrhage?
Subarachnoid hemorrhage (SAH) is a serious, life-threatening event caused by a ruptured aneurysm (bleeding into the space surrounding the brain). Treatment focuses on stopping the bleeding, restoring normal blood flow, relieving the pressure on the brain, and preventing cerebral vasospasm.2
What is Cerebral Vasospasm?
Cerebral vasospasm is a common complication that may occur in SAH patients. It is a narrowing of cerebral arteries which reduces blood flow to regions of the brain. If the reduction in blood flow is severe or remains untreated, permanent disability and even death can occur. Mortality and morbidity due to vasospasm ranges from 14-36% of patients.2,3 Patients are at highest risk for vasospasm between days 5 and 10 after SAH. Irritating blood by-products cause the walls of an artery to contract and spasm.4
CAUTION-Investigational device. Limited by Federal (or United States) law to investigational use.
1 Bardutzky J et al. EARLYDRAIN- Outcome after Early Lumbar CSF-Drainage in Aneurysmal Subarachnoid Hemorrhage: Study Protocol for a Randomized Controlled Trial. Trials 12 (2011):203.
2 US Brain Aneurysm Foundation, https://www.bafound.org/aneurysm-complications.
3 Lindegaard K et al. Clinical course of spontaneous subarachnoid hemorrhage: a population based study in Kind County, Washington. Neurologi. 1993;43:712-718.